NR-53876单克隆抗SARS冠状病毒重组人IgG1,克隆CR3022(产自本氏烟草)(单克隆抗体）
产品图片
货号/SKU
NR-53876
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-53876?? Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)(Monoclonal Antibodies)|SARS Coronavirus|Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)| -60°C or colder |Novici Biotech LLCAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana), NR-53876.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Antibody Class: IgG1
Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-53876 was produced in Nicotiana benthamiana tobacco plants using a transient plant expression system and purified from the total plant homogenate using protein A chromatography. This antibody preparation differs from BEI Resources NR-52392 only in the method used to extract the recombinant product from the expression host plants prior to affinity purification; NR-52392 was purified from an extracellular fraction and NR-53876 was extracted from total plant homogenate. Plant made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.
Note: Questions related to NR-53876 may be addressed by contacting info@novicibiotech.com.
NR-53876 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent in vitro assay. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays.
Applications include western blot analysis, immunofluorescence, ELISA and neutralization.
Each vial of NR-53876 contains approximately 100 ?L of purified monoclonal antibody in PBS.
Antibody Class: IgG1
Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-53876 was produced in Nicotiana benthamiana tobacco plants using a transient plant expression system and purified from the total plant homogenate using protein A chromatography. This antibody preparation differs from BEI Resources NR-52392 only in the method used to extract the recombinant product from the expression host plants prior to affinity purification; NR-52392 was purified from an extracellular fraction and NR-53876 was extracted from total plant homogenate. Plant made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.
Note: Questions related to NR-53876 may be addressed by contacting info@novicibiotech.com.
NR-53876 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent in vitro assay. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays.
Applications include western blot analysis, immunofluorescence, ELISA and neutralization.
Each vial of NR-53876 contains approximately 100 ?L of purified monoclonal antibody in PBS.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
抗体类：IgG1
通过免疫噬菌体展示文库制备人单克隆抗体CR3022，由促进的严重急性呼吸综合征冠状病毒（SARS-COV）患者的淋巴细胞构成. CR3022是靶向SARS-COV的穗糖蛋白的受体结合结构域（RBD）的中和抗体.使用瞬态植物表达系统在尼古罗尼亚·玻璃南烟草中产生NR-53876，并使用蛋白质A色谱法从总植物均匀均匀纯化.该抗体制剂仅不同于BEI资源NR-52392，其仅在用于在亲和纯化之前从表达宿主植物中提取重组产物的方法中;从细胞外级分纯化NR-52392，并从总植物匀浆中提取NR-53876.植物制成的抗体CR3022具有将引入人IgG1分子中的互补确定区域（CDR）序列. CR3022的表位与来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的S糖蛋白RBD中的ACE2结合位点不重叠. CR3022靶向高度保守的表位，使得SARS-COV-2和SARS-COV之间的交叉反应结合能够.
注意：与NR-53876相关的问题可以通过联系 info@novicibiotech.com .
NR-53876特异于S糖蛋白，已被证明以中和SARS-COV. CR3022识别到在减少和非还原条件下与人IgG1 Fc结构域（S1-Fc）融合的全长SARS-COV-2 S1蛋白，以及单独的六征组氨酸标记的糖蛋白RBD，在Western印迹中分析;然而，CR3022在近期的体外测定中没有中和SARS-COV-2. CR3022效果效果，如ELISA和BIOLAYER干涉测定（BLI）结合测定法所确定的.
应用包括蛋白质印迹分析，免疫荧光，ELISA和中和.
每个小瓶NR-53876在PBS中含有约100μl纯化的单克隆抗体.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2024-01-21
2021-10-31
2019-05-08
2022-04-01
2021-12-21
2022-04-01
2022-04-01
2021-12-21
2022-06-17
2021-12-21
2024-01-21
2024-01-21
2023-11-12
2024-05-19